BrainChip

Thesis

BrainChip (ASX: BRN / OTCQX. BRCHF) is the only publicly traded pure-play neuromorphic chip company. It trades at AUD 0.145, down 94% from its 2022 high of AUD 2.34, with effectively zero revenue ($398K in 2024). The bull case rests entirely on the AKD1500 production ramp in 2026 and the Akida Pulsar mass-market neuromorphic MCU. The bear case is strong. 13 years of promises with no meaningful revenue. At sub-$400K in annual revenue, BrainChip is barely a going concern from a commercial perspective. However, it provides the only liquid retail access to the neuromorphic computing thesis, which gives it a scarcity premium. As the closest public proxy for biological computing (Cortical Labs, FinalSpark, and Koniku are all private), BrainChip captures speculative interest from investors who believe brain-inspired computing will become necessary as AI power demands scale. The company needs the AKD1500 to generate real revenue or it risks becoming another zero-revenue deep tech story. This is a binary bet. Either the 2026 production ramp delivers meaningful revenue, or the multi-year decline continues.

Catalysts

• +AKD1500 neuromorphic chip production ramp scheduled for 2026
• +Akida Pulsar mass-market neuromorphic MCU targeting broader adoption
• +Only liquid public proxy for the biological/neuromorphic computing thesis

Risks

• -13 years of promises with effectively zero revenue ($398K in 2024)
• -94% decline from 2022 highs suggests sustained loss of investor confidence
• -Binary outcome. AKD1500 must deliver or the stock likely trends to zero

Common questions